Atlas Trials

Study Evaluating the Safety and Efficacy of Eribulin Mesilate in Combination With Irinotecan Hydrochloride in Children With Refractory or Recurrent Solid Tumors

Clinical trial NCT03245450 · COMPLETED

Trial details

NCT number
NCT03245450
Sponsor
Eisai Inc.
Status
COMPLETED
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Refractory or Recurrent Solid TumorsRhabdomyosarcomaNon-Rhabdomyosarcoma Soft Tissue SarcomaEwing Sarcoma
Start date
2018-03-05
Primary completion
2021-05-17
Enrollment
40

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.